GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Equity-to-Asset
Switch to:

Biogen (MEX:BIIB) Equity-to-Asset

: 0.55 (As of Dec. 2022)
View and export this data going back to 2013. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biogen's Total Stockholders Equity for the quarter that ended in Dec. 2022 was MXN262,797 Mil. Biogen's Total Assets for the quarter that ended in Dec. 2022 was MXN481,624 Mil. Therefore, Biogen's Equity to Asset Ratio for the quarter that ended in Dec. 2022 was 0.55.

The historical rank and industry rank for Biogen's Equity-to-Asset or its related term are showing as below:

MEX:BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44   Med: 0.76   Max: 0.96
Current: 0.55

During the past 13 years, the highest Equity to Asset Ratio of Biogen was 0.96. The lowest was 0.44. And the median was 0.76.

MEX:BIIB's Equity-to-Asset is ranked worse than
53.62% of 1119 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs MEX:BIIB: 0.55

Biogen Equity-to-Asset Historical Data

The historical data trend for Biogen's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.49 0.44 0.46 0.55

Biogen Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.48 0.47 0.51 0.55

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Biogen's Equity-to-Asset falls in comparison to its industry or sector. The grey bar indicates the Equity-to-Asset's extreme value range as defined by GuruFocus.



Biogen Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Biogen's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=262797.12901154/481623.76084776
=0.55

Biogen's Equity to Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

Equity to Asset (Q: Dec. 2022 )=Total Stockholders Equity/Total Assets
=262797.12901154/481623.76084776
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Biogen Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Biogen's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines